TrioxNano
Programmable Medicine using synthetic DNA molecular machines
Company Overview
Snapshot
Founded in July 2015 by Roy Farfara, TrioxNano operates with 1–10 employees. The company has raised a total of $3.6M across two funding rounds. TrioxNano ceased operations in December 2024.
Business overview
TrioxNano develops programmable medicine solutions utilizing synthetic DNA molecular machines. The company's core technology focuses on a "Programmed Medicine Biosphere" to create therapeutic and diagnostic solutions. Its product portfolio includes P-ADC (Programmable Aptamer DNAzyme Conjugates) for targeted mRNA knockdown in cancer, P-DDP (Programmable Drug Delivery Platforms) for precise drug delivery, P-DST (. TrioxNano operates within the Health Tech & Life Sciences sector, specifically targeting pharmaceuticals and drug discovery and development, with a global market reach.
Log in to access full profile ›Company Intelligence Q&A
- What is TrioxNano's primary focus?
- TrioxNano focuses on developing programmable medicine solutions using synthetic DNA molecular machines for therapeutic and diagnostic applications.
- When was TrioxNano founded?
- TrioxNano was founded in July 2015.
- Who is the founder of TrioxNano?
- Roy Farfara is the founder and CEO of TrioxNano.
- What is the status of TrioxNano?
- TrioxNano ceased to operate in December 2024.
- What is TrioxNano's P-ADC technology?
- TrioxNano's P-ADC (Programmable Aptamer DNAzyme Conjugates) technology replaces analog components with digital aptamers and programmed DNAzymes for highly targeted mRNA knockdown, addressing challenges in cancer treatment.